Saturday, October 22, 2016 1:43:12 PM
While there may be nuggets of information in Gene's letter, I agree with posters saying that his excuse for taking so long is feeble, at best.
The market's reaction to the letter will be most telling. Though the views of certain individuals may be interesting, the take of any single individual is of only minor import most likely just an expression pre-existing beliefs, pro or con, about the company and its management.
If prices can hold above the support zone I've mentioned in several posts ( 1.45 - 1.55) we can conclude the letter did not change sentiment. A break below that support will be a distinct indication of a ratcheting down of expectations. A breakout to the upside will signal a positive reaction. The key resistance zone is between 1.70 & 1.80. I consider an upside breakout unlikely but I will let the market tell me.
There is a large short position in NNVC, equal to about 35 days of average daily volume. Large short positions in small cap stocks is generally a bearish signal. But the bears aren't always right and if an upside breakout were to occur due to the announcement of significant material progress a move back to the March highs ( 3.44) would occur rapidly as shorts cover.
My expectation is for a CEO letter that shows no material progress - something the shorts are already anticipating, and for a downside breakout to occur. Target range 50 cents to 1.00.
Trendliner
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM